China NMPA grants breakthrough therapy designation to Kelun-Biotech’s sacituzumab tirumotecan in combo with immunotherapy pembrolizumab for first-line treatment of PD-L1-positive NSCLC ...
From broad R&D to validated platforms, HPQ advances fumed silica, battery materials, and hydrogen while realigning capital ...
The 2026 Industrial Reset is here. Explore how Nvidia’s Alpamayo, Hyundai’s Atlas, and India’s new e-B-4 visa are ...
The stratospheric drone, independently developed by the Korea Aerospace Research Institute (KARI), is a solar-powered drone ...
M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation ...
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics ...
Ambitions to build America's very own bullet train are on track for 2026, California's High Speed Rail Authority tells ...
This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...
Hyundai Motor Group debuts real-world human-centered AI Robotics at CES 2026 The Group to secure optimal capabilities, ...
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the ...
Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback